Increased serum levels of the specific AGE-compound methylglyoxal-derived hydroimidazolone in patients with type 2 diabetes

Metabolism: Clinical and Experimental

Volumn 52, Issue 2, 2003, Pages 163-167

  Kilhovd, Bente K ^a,b,c   Giardino, I ^a,b,c   Torjesen, P A ^a,b,c   Birkeland, K I ^a,b,c   Berg, T J ^a,b,c   Thornalley, P J ^a,b,c   Brownlee, M ^a,b,c   Hanssen, K F ^a,b,c  

^a AKER UNIVERSITY HOSPITAL   (Norway)

^b ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^c UNIVERSITY OF ESSEX   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

6 N CARBOXYMETHYLLYSINE; ADVANCED GLYCATION END PRODUCT; ALBUMIN; ANTIBODY; EUROPIUM; GLUCOSE; HEMOGLOBIN A1C; HYDROIMIDAZOLONE; METFORMIN; METHYLGLYOXAL; MONOCLONAL ANTIBODY; MOUSE IMMUNOGLOBULIN G ANTIBODY; N ALPHA ACETYL N DELTA (5 HYDRO 5 METHYL) 4 IMIDAZOLONE; POLYCLONAL ANTIBODY; SULFONYLUREA; UNCLASSIFIED DRUG;

ACCURACY; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DIET RESTRICTION; DISEASE DURATION; DOSE RESPONSE; DRUG BLOOD LEVEL; FEMALE; GLUCOSE BLOOD LEVEL; GLYCATION; HUMAN; IMMUNOFLUORESCENCE TEST; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SERUM; STATISTICAL ANALYSIS;

EID: 0037302018     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1053/meta.2003.50035     Document Type: Article

References (41)

1. Greene DA, Lattimer SA, Sima AAF: Sorbitol, phosphoinositides, and sodium-potassium-ATPase in the pathogenesis of diabetic complications. N Engl J Med 316:599-606, 1987
2. Baynes JW, Thorpe SR: Role of oxidative stress in diabetic complications. A new perspective on an old paradigm. Diabetes 48:1-9, 1999
3. Koya D, King GL: Protein kinase C activation and the development of diabetic complications. Diabetes 47:859-866, 1998
4. Brownlee M: Glycation and diabetic complications. Diabetes 43:836-841, 1994
5. Haffner SM, Lehto S, Rönnemaa T, et al: Mortality from coronary heart disease in subjects with type 2 diabetes and in nondiabetic subjects with and without prior myocardial infarction. N Engl J Med 339:229-234, 1998
6. Stratton IM, Adler AI, Neil AW, et al: Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): Prospective observational study. BMJ 321:405-412, 2000
7. Brownlee M, Cerami A, Vlassara H: Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N Engl J Med 318:1315-1321, 1988
8. Vlassara H, Bucala R, Striker L: Pathogenetic effects of advanced glycosylation: Biochemical, biologic, and clinical implications for diabetes and aging. Lab Invest 70:138-151, 1994
9. Nakamura Y, Horii H, Nishino T et al: Immunohistochemical localization of advanced glycosylation endproducts (AGEs) in coronary atheroma and cardiac tissue in diabetes mellitus. Am J Pathol 143:1649-1656, 1993
10. ε-(carboxymethyl) lysine in human tissues in diabetes and aging. J Clin Invest 99:457-468, 1997
11. Berg TJ, Bangstad H-J, Torjesen PA, et al: Advanced glycation end products in serum predict changes in the kidney morphology of patients with insulin-dependent diabetes mellitus. Metabolism 46:661-665, 1997
12. Kilhovd BK, Berg TJ; Birkeland KI, et al: Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22:1543-1548, 1999
13. Shinohara M, Thornalley PJ, Giardino I, et al: Overexpression of glyoxalase-1 in bovine endothelial cells inhibits intracellular advanced glycation endproduct formation and prevents hyperglycemia-induced increases in macromolecular endocytosis. J Clin Invest 101:1142-1147, 1998
14. Thornalley PJ: The glyoxalase system: New developments towards functional characterization of a metabolic pathway fundamental to biological life. Biochem J 269:1-11, 1990
15. McLellan AC, Thornalley PJ, Benn J, et al: Glyoxalase system in clinical diabetes mellitus and correlation with diabetic complications. Clin Sci 87:21-29, 1994
16. Phillips SA, Thornalley PJ: The formation of methylglyoxal from triose phosphates. Investigations using a specific assay for methylglyoxal. Eur J Biochem 212:101-105, 1993
17. Ray S, Ray M: Isolation of methylglyoxal synthase from goat liver. J Biol Chem 256:6230-6233, 1981
18. Koop D, Casazza JP: Identification of ethanol-inducible P-450 isozyme 3a as the acetone and acetol monooxygenase of rabbit microsomes. J Biol Chem 260:13607-13612, 1985
19. Lyles GA, Chalmes J: The metabolism of aminoacetone to methylglyoxal by semicarbazide-sensitive amine oxidase in human umbilical artery. Biochem Pharmacol 43:1409-1414, 1992
20. Lo TWC, Westwood ME, McLellan AC, et al: Binding and modification of proteins by methylglyoxal under physiological conditions. J Biol Chem 269:32299-32305, 1994
21. Frye EB, Degenhardt TP, Thorpe SR, et al: Role of the Maillard reaction in aging of tissue proteins. J Biol Chem 273:18714-18719, 1998
22. Westwood ME, Argirov OK, Abordo EA, et al: Methylglyoxal-modified arginine residues - A signal for receptor-mediated endocytosis and degradation of proteins by monocytic THP-1 cells. Biochim Biophys Acta 1356:84-94, 1997
23. Thornalley PJ: Glutathione-dependent detoxification of α-oxoaldehydes by the glyoxalase system: Involvement in disease mechanisms and antiproliferative activity of glyoxalase I inhibitors. Chem-Biol Interact 111-112:137-151, 1998
24. Lo TWC, Selwood T, Thornalley PJ: The reaction of methylglyoxal with aminoguanidine under physiological conditions and prevention of methylglyoxal binding to plasma proteins. Biochem Pharm 48:1865-1870, 1994
25. Giardino I, Thornalley PJ, Edelstein D, et al: Generation and characterization of a monoclonal antibody against AGEs that induce endothelial cell dysfunction. Diabetes 47:A123, 1998 (suppl 1, abstr)
26. Westwood ME, Thornalley PJ: Molecular characteristics of methylglyoxal-modified bovine and human serum albumins. Comparison with glucose-derived advanced glycation endproduct-modified serum albumins. J Prot Chem 14:359-372, 1995
27. Makita Z, Vlassara H, Cerami A, et al: Immunochemical detection of advanced glycosylation end products in vivo. J Biol Chem 267:5133-5138, 1992
28. Clausen JT, Christensen M, Skovsted I, et al: Antibodies against in vitro generated AGE: Specificity and applicability to assays for in vivo AGE. Diabetologia 40:A588, 1997 (abstr)
29. ε-(carboxymethyl)lysine is increased in serum from children and adolescents with type 1 diabetes. Diabetes Care 21:1997-2002, 1998
30. Friedewald WT, Levy RI, Fredrickson DS: Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without the use of the preparative ultracentrifuge. Clin Chem 18:499-502, 1972
31. Birkeland KI, Rishaug U, Hanssen KF, et al: NIDDM: A rapid progressive disease. Results from a long-term, randomised, comparative study of insulin or sulphonylurea treatment. Diabetologia 39:1629-1633, 1996
32. Dorrian CA, Cathcart S, Clausen J, et al: Factors in human serum interfere with the measurement of advanced glycation endproducts. Cell Mol Biol 44:1069-1079, 1998
33. ε-(carboxyethyl)lysine, a product of the chemical modification of proteins by methylglyoxal, increases with age in human lens proteins. Biochem J 324:565-579, 1997
34. Beisswenger PJ, Howell SK, O'Dell RM, et al: α-Dicarbonyls increase in the postprandial period and reflect the degree of hyperglycemia. Diabetes Care 24:726-732, 2001
35. Shamsi FA, Partal A, Sady C, et al: Immunological evidence for methylglyoxal-derived modifications in vivo. J Biol Chem 273:6928-6936, 1998
36. Niwa T, Katsuzaki T, Ishizaki Y, et al: Imidazolone, a novel advanced glycation end product, is present at high levels in kidneys of rats with streptozotocin-induced diabetes. FEBS Letters 407:297-302, 1997
37. 1c as markers of diabetic complications. Diabetes 48:870-880, 1999
38. Singh R, Barden A, Mori T, et al: Advanced glycation end-products: A review. Diabetologia 44:129-146, 2001
39. Abordo EA, Thornalley PJ: Synthesis and secretion of tumour necrosis factor-α by human monocytic THP-1 cells and chemotaxis induced by human serum albumin derivatives modified with methylglyoxal and glucose-derived advanced glycation endproducts. Immunol Lett 58:139-147, 1997
40. Raskin P, Cattran D, Williams M, et al: Pimagedine (PG) reduces progression of retinopathy and lowers lipid levels in patients with type 1 diabetes mellitus (DM). J Am Soc Nephrol 10:A0914, 1999 (abstr)
41. Appel G, Bolton K, Freedman B, et al: Pimagedine (PG) lowers total urinary protein (TUP) and slows progression of overt diabetic nephropathy in patients with type 1 diabetes mellitus (DM). J Am Soc Nephrol 10:A0786, 1999 (abstr)